Popular Searches: Recombinant Antibody MHC Tetramer T cell Receptor Scaffold Protein
+ Filter
Loading...
Custom Services order now ship next day

Anti-HER3 Recombinant Antibody Products

Antibody-like Scaffold Protein Products Antibody Magnetic Beads AbPlus Recombinant Antibody Products Functional Antibody Products Formats

Creative Biolabs offers comprehensive technical support to assist customers with any issues or questions related to the HER3 recombinant antibody product. This includes guidance on how to use the antibody effectively in various applications, troubleshooting assistance for unexpected results, and recommendations for optimal experimental conditions. The team of experts is available to provide personalized support and expertise, ensuring that customers can achieve the best results with the HER3 recombinant antibody.

HER3: A Promising Target for Cancer Therapy

As a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, HER3, also known as ERBB3, plays a vital role in various cellular processes including cell proliferation, survival, and differentiation. Dysregulation of HER3 signaling has been linked to the development and progression of various types of cancers, making it an attractive therapeutic target for cancer treatment. Except for cancer, HER3 has also been implicated in the development of resistance to targeted therapies in different types of cancers.

Anti-HER3 Recombinant Antibody Products

Our list of anti-HER3 recombinant antibody products is designed to specifically bind to HER3, inhibiting its activity and potentially slowing down tumor growth. These HER3 antibodies have been developed using advanced recombinant technology to ensure high specificity and efficacy.

Table 1. Featured anti-HER3 recombinant antibody products at Creative Biolabs.

Cat. No. Product Name Target Species Host Species Applications
TAB-189 Human Anti-ERBB3 Recombinant Antibody (TAB-189) Human Human IgG1 FC, IP, ELISA, Neut, FuncS, IF, ICC
TAB-H47 Anti-Human ERBB3 Recombinant Antibody Human Human IgG1, κ ELISA, Inhib
TAB-892 Anti-Human ERBB3/ErbB 3 Recombinant Antibody Human Human IgG2 IF, IP, Neut, FuncS, ELISA, FC, ICC
TAB-422CQ Anti-Human ERBB3 Recombinant Antibody Human Human IgG1, κ ELISA, IHC, IF, IP, FCM, Blocking
PABL-086 Human Anti-ERBB3 Recombinant Antibody Human Human IgG ELISA, WB, IF, FuncS

Creative Quality Control

Creative Biolabs' HER3 recombinant antibody products have implemented a rigorous quality control process to ensure the high quality and efficacy of their products. This includes rigorous testing for purity, specificity, and activity of the antibodies. Our R&D team also conducts regular antibody quality audits and inspections to maintain consistency in their manufacturing process and product performance. By taking these quality control measures, you can be confident in the reliability and effectiveness of our anti-HER3 recombinant antibody products.

Fig.1 SDS-PAGE analysis. (Creative Biolabs Original)Fig.1 SDS-PAGE analysis of anti-HER3 antibody
(Cat# TAB-189, Creative Biolabs).

Fig.2 SEC-HPLC analysis. (Creative Biolabs Original)Fig.2 SEC-HPLC analysis of anti-HER3 antibody (Cat#
TAB-189, Creative Biolabs).

Fig.3 WB analysis. (Creative Biolabs Original)Fig.3 WB analysis of anti-HER3 antibody (Cat#
TAB-189, Creative Biolabs).

Fig.4 ELISA analysis. (Creative Biolabs Original)Fig.4 ELISA analysis of anti-HER3 antibody
(Cat# TAB-189, Creative Biolabs)

Fig.5 In vitro inhibitory activity assay. (Creative Biolabs Original)Fig.5 In vitro inhibitory activity assay of anti-HER3 antibody
(Cat# PABL-086, Creative Biolabs).

Fig.6 In vivo activity assay. (Creative Biolabs Original)Fig.6 In vivo activity assay of anti-HER3 antibody
(Cat# PABL-086, Creative Biolabs).

Customer Reviews

Excellent
Ha**a
Human Anti-ERBB3 Recombinant Antibody (CAT#: PABL-086)
I recently purchased this anti-HER3 recombinant antibody (CAT#: PABL-086) for my experiments and I have been extremely impressed with its performance. The antibody worked well in my Western blot and immunofluorescence assays, providing clear and reliable data. I will buy from this company again if there is a demand in the future.
04/May/2022 0 Likes
Excellent
M***y
Anti-Human ERBB3 Recombinant Antibody (CAT#: TAB-H47)
I purchased the HER3 antibody (TAB-H47) for my research project and I was impressed with the quality of the product. The antibody performed well in my assays and gave consistent results. I will be purchasing from this company again in the future.
11/Jan/2024 1 Likes

Anti-HER3 Recombinant Antibody Production

Our serum-free mammalian cell expression platform utilizes synthetic biology techniques to engineer antibodies that target the HER3 receptor for cancer therapy.

Featured Anti-HER3 Recombinant Antibody Production Platforms

Fig.7 Milligram-scale. (Creative Biolabs Original)Fig.7 Milligram-scale anti-HER3 recombinant antibody production.

Fig.8 Gram-scale. (Creative Biolabs Original)Fig.8 Gram-scale anti-HER3 recombinant antibody production.

Anti-HER3 Recombinant Antibody Modalities

Anti-HER3 recombinant antibody modalities are biologically engineered molecules that specifically target and bind to the HER3 receptor. These antibodies can be designed to block the activation of HER3 signaling pathways, leading to inhibition of tumor growth and potentially inducing cell death in cancer cells. Some anti-HER3 recombinant antibody modalities can also be conjugated with toxins or other therapeutic agents to enhance their anti-cancer effects.

Fig.9 HER3 antibody production and modalities. (Creative Biolabs Original)Fig.9 Full length anti-HER3 recombinant antibody production and modalities.

Alternative Names

ERBB3; FERLK; LCCS2; ErbB-3; c-erbB3; erbB3-S; MDA-BF-1; c-erbB-3; p180-ErbB3; p45-sErbB3; p85-sErbB3; receptor tyrosine-protein kinase erbB-3; human epidermal growth factor receptor 3; proto-oncogene-like protein c-ErbB-3; tyrosine kinase-type cell surface receptor HER3; v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3.

Background

This gene encodes a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases. This membrane-bound protein has a neuregulin binding domain but not an active kinase domain. It therefore can bind this ligand but not convey the signal into the cell through protein phosphorylation. However, it does form heterodimers with other EGF receptor family members which do have kinase activity. Heterodimerization leads to the activation of pathways which lead to cell proliferation or differentiation. Amplification of this gene and/or overexpression of its protein have been reported in numerous cancers, including prostate, bladder, and breast tumors. Alternate transcriptional splice variants encoding different isoforms have been characterized. One isoform lacks the intermembrane region and is secreted outside the cell. This form acts to modulate the activity of the membrane-bound form. Additional splice variants have also been reported, but they have not been thoroughly characterized.

Public Drug Information Targeting HER3

Table 2. Public drug targeting HER3.

Drug Type Company Condition Organization
Peptides Digestive/Gastrointestinal Cancer Therapy
Non-Small Cell Lung Cancer Therapy 		Cancer, lung
Cancer, lung (non-small cell) (NSCLC)
Cancer, solid tumor
Digestive-gastrointestinal cancer 		PharmaMar (Originator)
Biologics Breast Cancer Therapy
Colorectal Cancer Therapy
Lung Cancer Therapy 		Cancer, breast
Cancer, colorectal
Cancer, lung 		3SBio (Originator)
Biologics Anticancer Drugs Cancer Biokin Pharmaceutical (Originator)
SystImmune (Originator)

(Disclaimer: The information in this table is just for knowledge sharing and not for marketing or sales purposes.)

Clinical Drug Information Targeting HER3

Table 3. Therapeutic approaches targeting HER3 in clinical development.

Development Phase Company Condition Indication
Pre-Registered Daiichi Sankyo Cancer, lung (non-small cell) (NSCLC) Treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) previously treated with two or more systemic therapies
Pre-Registered Merus Cancer, lung (non-small cell) (NSCLC) Treatment of patients with neuregulin 1 fusion (NRG1)-positive non-small cell lung (NSCLC)
Phase III Biokin Pharmaceutical Cancer, breast Treatment of HR-positive HER2-negative advanced/recurrent/metastatic breast cancer after failure of at least one line of chemotherapy
Phase II/III Biokin Pharmaceutical Cancer, lung (non-small cell) (NSCLC) Treatment of advanced/metastatic non-small cell lung cancer (NSCLC) either in patients with EGFR exon20ins mutation or in patientswith non-(EGFR TKI)-sensitizing mutation who progressed on EGFR TKI therapy, in combination with osimertinib
Phase II Merrimack Cancer, esophagus In combination with paclitaxel and with or without trastuzumab in patients with Her2 expressing carcinomas of the distal esophagus, gastroesophageal (GE) junction and stomach who have failed front line metastatic or locally advanced therapy
Phase II Genentech Cancer, colorectal, metastatic In combination with FOLFIRI in second line in patients with KRAS wild-type metastatic colorectal cancer
Phase II PharmaMar Cancer, lung (non-small cell) (NSCLC)
Phase II Salubris Biotherapeutics Heart failure with preserved ejection fraction In patients with heart failure with preserved ejection fraction
Phase II Celldex Therapeutics Cancer, head and neck (squamous cell carcinoma) In patients with advanced head and neck squamous cell carcinoma whose tumors progressed after previous cetuximab treatment, in combination with cetuximab
Phase II Amgen Cancer
Phase II AstraZeneca Cancer, gastrointestinal Treatment of metastatic, gastric or gastro-oesophageal junction cancer in combination with chemotherapy
Phase II Merrimack Cancer, lung (non-small cell) (NSCLC), metastatic Treatment of metastatic NSCLC in combination with erlotinib in patients without EGFR mutation and have recurred or progressed following at least one chemotherapy containing regimen and who have not received prior EGFR targeted therapy; As a triple-negative neoadjuvant
Phase II BioNTech Cancer, solid tumor Treatment of HER3-positive advanced/metastatic solid tumors
Phase I/II Duality Biologics Cancer, solid tumor Treatment of HER3-expressing advanced/metastatic solid tumors
Phase I/II Hummingbird Bioscience Cancer, solid tumor Treatment of HER3-expressing advanced solid tumors, including NRG1 gene fusion-positive tumors; In combination with docetaxel with or without cetuximab in patients with locally advanced or metastatic squamous non-small cell lung cancer
Phase I/II Symphogen Cancer In adult patients with epithelial malignancies that are locally advanced or metastatic, and that are refractory to standard therapy
Phase I Daiichi Sankyo Cancer PET/CT Imaging
Phase I Roche Cancer, solid tumor
Phase I AVEO Oncology Cancer, solid tumor Treatment of advanced or metastatic solid tumors
Phase I ISU ABXIS Cancer, solid tumor In patients with advanced solid tumors; as monotherapy or in combination with cetuximab
Phase I Bristol-Myers Squibb Cancer, solid tumor In patients with advanced solid malignancies that express Her2.
Phase I/II Novartis Cancer, head and neck (squamous cell carcinoma) As monotherapy or in combination with cetuximab
Phase I GSK Cancer, solid tumor Treatment of advanced HER3-positive solid tumors
Phase I Roche Cancer, breast, metastatic In combination with pertuzumab and paclitaxel in patients with metastatic breast cancer expressing HER3 and HER2 protein
Phase I Molecular Partners Cancer, solid tumor In patients with unresectable, locally advanced, or metastatic HER2-positive solid tumors
Phase I Regeneron Cancer Alone or in combination with erlotinib or cetuximab
Phase I Zensun Cancer, breast Treatment of breast cancer with ErbB2 overexpression
Phase I China National Pharma Group (SINOPHARM) Cancer, solid tumor For the treatment of adult patients with advanced malignant solid tumors
Phase I Merrimack Cancer, solid tumor Treatment of advanced solid tumors, such as hepatocellular carcinoma
Preclinical Endeavor BioMedicines Cancer, solid tumor
Preclinical MediaPharma Cancer
Preclinical MediaPharma Cancer Localization of HER3 expressing cancer by Immino-PET analysis
Preclinical MediaPharma Cancer
Preclinical MediaPharma Cancer Localization of HER3 expressing cancer by Immino-PET analysis
Preclinical MediaPharma Cancer
Preclinical Symphogen Cancer
Preclinical Takis Cancer, solid tumor
Preclinical SunRock Biopharma Cancer, solid tumor
Preclinical Tharimmune Cancer
Preclinical Zymeworks Cancer, solid tumor Such as pancreatic, prostate, breast, stomach and colorectal cancer

(Disclaimer: The information in this table is just for knowledge sharing and not for marketing or sales purposes.)

Are you in need of a high-quality anti-HER3 recombinant antibody for your research? Look no further than us! Our antibodies are meticulously tested and produced to ensure the highest level of specificity and sensitivity. Our knowledgeable HER3 antibody R&D team is ready to assist you with any questions or concerns, and you can be confident that you will receive the best possible assistance. Please do not hesitate to contact us to learn more about our HER3 antibody products. Let us be your partner in future projects that advance science and make a difference in the fight against cancer.

Related Diseases
EGFR Tyrosine Kinase Inhibitor Resistance EGFR Tyrosine Kinase Inhibitor Resistance
Related Signaling Pathways
ErbB Signaling Pathway ErbB Signaling Pathway
More Infomation

Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us

Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag

For Research Use Only. Not For Clinical Use.

  • 0
  • 0
Cart
    Inquiry
    Go to compare

    Go to compare